60 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
13 May 24
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:15am
candidates are designed to treat, expectations for the markets for certain therapeutics, our ability to execute our clinical and regulatory goals
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
candidates are designed to treat, expectations for the markets for certain therapeutics, our ability to execute our clinical and regulatory goals
8-K
EX-99.1
foobov012hvuoy4v1
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
EX-99.1
wq54k5uw9dozzei5cp
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
424B5
circlslgt
15 Jun 23
Prospectus supplement for primary offering
4:54pm
8-K
EX-99.1
ij60d2x7hv3tu12
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-99.1
stdupgl kopbs
10 Apr 23
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
8:30am
8-K
EX-99.1
ggth2
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am
8-K
EX-99.1
ishws073rhxu5
11 May 22
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
8:30am
8-K
EX-99.1
pkhksbwc5 cjh
23 Mar 22
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
4:05pm
8-K
EX-99.1
dp1qwqrrdwa4snloaq
22 Dec 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
narmax16sj7mu
15 Nov 21
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development
8:00am
424B5
lcn 6uw0qny8p3d
5 May 21
Prospectus supplement for primary offering
4:01pm